GlaxoSmithKline has opened two continuous manufacturing facilities in Jurong, Singapore, following a $95.6 million investment as part of the company’s 10-year strategic plan in Singapore. The facilities expand an existing production building and aim to shorten timelines to produce daprodustat.   Daprodustat, a new chemical entity (NCE) will be produced at the additional facility and the company expects the use of continuous manufacturing to reduce production time. The drug is currently in Phas...